

FARMINGDALE, N.Y. , Oct. 21, 2013 /PRNewswire/ -- Misonix, Inc. (NASDAQ: [MSON](#)), an international surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic products for spine surgery, skull based surgery, neurosurgery, wound debridement, cosmetic surgery, laparoscopic surgery and other surgical applications, recently participated in the 2013 Diabetic Limb Salvage Conference held at the JW Marriott in Washington, DC from October 10th – 12th, 2013.

Misonix exhibited and presented the newest addition to its wound care line of devices, the SonicOne® O.R. Ultrasonic Surgical Debridement System. The SonicOne O.R. is an innovative surgical device that allows surgeons to address the challenges chronic wounds present to them, the patient, and the health-care system. SonicOne O.R. establishes a new standard in surgical wound bed preparation, an essential first step in the wound healing process. Use of the SonicOne O.R. system provides controlled tissue removal, decreased healing times, reduced bleeding and a reduction of biofilm.

In addition to exhibiting at the conference, Misonix also participated in two "Gloves on Cadaver Workshops" on Saturday October 12th, where participants were able to use the device in simulated scenarios. The Wound Care 101 workshop was moderated by Katherine J.S. Hubley, RN , CWCN, manager of the Wound Care Clinic at MedStar Georgetown University Hospital and the Basic Soft Tissue Technique workshop was moderated by Dr. John S Steinberg, DPM, Associate Professor and Co-Director of Center for Wound Healing at MedStar

Georgetown University
Hospital.

More than 100 surgeons and wound care professionals had an opportunity to trial the SonicOne O.R. technology at the conference. Faculty member Peter A. Blume, DPM, FACFAS, Assistant Clinical Professor of Surgery at the Yale School of Medicine in New Haven, Connecticut stated, "SonicOne O.R. was one of the true highlights in the teaching labs at this year's Diabetic Limb Salvage Conference. It represents one of the newest technologies for wound debridement and wound bed preparation and may finally allow for significant reduction in biofilm production, which inhibits wound healing. The demonstrated safety and efficacy of the SonicOne O.R. ultrasonic debridement system has the potential to finally transform operative wound debridement in a way that we have not seen in the recent past."

Michael A. McManus, Jr., President and Chief Executive Officer of Misonix comments, "We had an extremely busy DLS meeting with approximately 100 attendees visiting our exhibit seeking a product demonstration. The awareness of SonicOne O.R. is rapidly increasing, peer-to-peer referrals are growing and hospitals are increasingly asking for trials in their operating rooms."

About the MedStar Georgetown Diabetic Limb Salvage Conference The conference is intended to better equip each member of the health care team with the education and resources needed to heal wounds and prevent amputations. It features a prominent multidisciplinary faculty that promotes the importance of every member of the team. The course is designed for health care practitioners of all specialties and will focus on an evidence-based approach to each aspect of limb salvage. The meeting format included didactic lectures, hands-on workshops, specialty symposia, and live surgical case demonstrations for the purpose of providing a live interactive learning experience.

About Misonix Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of \$3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com

Safe Harbor Statement *With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.*

SOURCE Misonix, Inc.

RELATED LINKS <http://www.misonix.com>